The KEYNOTE-355 study explores KEYTRUDA (pembrolizumab) in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer, whose tumours express PD-L1 with a CPS ≥10 and who have not received prior chemotherapy for metastatic disease.

CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1

Refer to the Summary of Product Characteristics and Risk Minimisation Materials available on the emc website before prescribing, in order to help reduce the risk associated with KEYTRUDA.